Tissue Diagnostics Market Size - By Product (Consumables, Instruments), Technology (Immunohistochemistry (IHC), In-situ Hybridization (ISH), Special Staining, Digital Pathology, Management), Application (Breast Cancer, Prostate Cancer, Lung Cancer, Lymphoma, Gastric Cancer), End-use (Hospitals, Research Laboratories, Pharmaceutical Companies, CROs) – Global Forecast to 2032

Tissue Diagnostics Market Size

Tissue Diagnostics Market size was valued at over USD 5 billion in 2022 and is projected to reach more than USD 11 billion by 2032.
 

Tissue diagnostics, also known as histopathology or surgical pathology, is a branch of medicine that involves the examination and analysis of tissue samples obtained from patients. It is a crucial aspect of diagnosing various diseases, including cancer and other disorders. Rising healthcare expenditure and growing awareness regarding cancer and other disorders has stimulated the demand for tissue diagnostic.

In developing countries, there has been a rising need for private diagnostic laboratories because of low level of service available from the public sector. For instance, in South Africa, there is a mix of public and private laboratories. However, major provider of diagnostic services is National Health Laboratory Service (NHLS) with a nationwide network of over 265 pathology laboratories. The growing awareness about disease diagnosis and prevention has accelerated demand for disease detection tests, thus positively impacting market growth.

COVID-19 Impact

COVID-19 significantly impacted the tissue diagnostics market gains during the pandemic. The use of tissue diagnostics for the COVID-19 diagnosis is primarily responsible for this. In order to comprehend the pathophysiology of the illness, interpret diagnostic histopathological findings in autopsies, biopsies, or surgical specimens, and assess the risk of occupational infectious hazard, it is imperative to know whether SARS-CoV-2 was present in the tissue of COVID-19 patients, according to a study published in the Journal of Pathology in March 2021. The industry was impacted by the pandemic's increased use of tissue diagnostics.

Tissue Diagnostics Market Trends

Growing adoption of unhealthy diet including excessive fat and sugar content coupled with lack of physical exercise has escalated number of people suffering from chronic conditions such as diabetes and cancer. Globally, cancer ranks as a primary cause of mortality and a significant roadblock to raising life expectancy. For instance, according to the World Health Organization (WHO) estimates, cancer is the one of the top causes of death before the age of 70 in 23 countries and the first/second main cause in 112 of 183 countries. The fact that cancer is becoming more prevalent as a leading cause of death is partially as a result of the notable declines in stroke and coronary heart disease mortality rates worldwide.
 

Tissue Diagnostics Market Analysis

Based on product, the market is segmented into consumables and instruments. Consumables are further bifurcated into kits, reagents, antibodies, probes. Instruments are further segmented into scanners, tissue processing systems, slide staining systems. The consumables segment held the largest revenue size over USD 3 billion in 2022 and is estimated to grow USD 7 billion by 2032. The field of tissue diagnostics has witnessed significant technological advancements in recent years. These advancements have led to the development of new and improved consumables that offer higher sensitivity, specificity, and automation capabilities.
 

Based on technology, the tissue diagnostics market is bifurcated into immunohistochemistry (IHC), In-situ hybridization (ISH), digital pathology, special staining, and management. The digital pathology segment is anticipated to witness highest CAGR at 8.6% by 2032. An upsurge in the adoption rate of whole-slide imaging (WSI) among the pathologists, serves as one of the primary factors driving the segment progression. WSI extracts unique tumour traits and measures each component of these characteristics to aid in cancer diagnosis and offer informative clinical measures for tumours.
 

Additionally, this technology streamlines workflow, reduces turnaround times, and enables faster consultation and collaboration among pathologists and other healthcare professionals.
 

Tissue diagnostics market is bifurcated based on the application that includes various fields of oncology such as breast cancer, gastric cancer, prostate cancer, lymphoma, lung cancer, others. The breast cancer segment is anticipated to grow over USD 2 billion by 2032. The is revenue is majorly due to an obesity, tobacco use, postmenopausal hormone therapy, excessive alcohol use, long-term active and passive smoking, and other lifestyle-related habits contribute to the development of breast cancer. Human papillomavirus (HPV) infections, prolonged breastfeeding, fewer pregnancies, radiation exposure in the past, and age-related difficulties are among the primary factors for a surge in the number of cases of breast cancer.
 

The tissue diagnostics market is segmented by end-use into hospitals, research laboratories, and pharmaceutical companies, CROs, and others. Hospitals segment dominated the global market accounting for more than 35% market share in 2022 and is estimated to witness significant revenue by 2032 on account of increased use and efficacy rates of tissue diagnostic treatments by hospitals. Physicians are rapidly shifting from traditional testing processes and to tissue-based diagnostic testing techniques. This is due tissue diagnostic tests shorten turnaround times when compared to traditional approaches.
 

U.S. tissue diagnostics market accounted for more than USD 1 billion in 2022 and will grow momentously more than USD 3 billion by 2032 because of high incidence rate of cancer. Several public programmes are in place to reduce cancer incidence and increase demand for cancer diagnosis supplements in the market for tissue diagnostics. The Cancer Prevention and Control Research Network is a Centres for Disease Control and Prevention flagship programme that focuses on cancer prevention in this region.
 

Tissue Diagnostics Market Share

Some of the notable key tissue diagnostics market players operating in the tissue diagnostics industry include

• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Siemens
• Danaher
• bioMérieux SA
• QIAGEN
• Becton Dickinson & Company
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Agilent Technologies, Inc
• GE Healthcare
• BioGenex
• Cell Signaling Technology, Inc.

Tissue diagnostics Industry News:

• In June 2022, F. Hoffmann-La Roche has announced the CE launch of the next-generation VENTANA DP 600 slide scanner. This high-capacity slide scanner delivers outstanding image quality of stained histology slides from patient tissue samples, allowing for simplicity of use and workflow flexibility in the pathology lab.
   

Tissue diagnostics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product (USD Million)

• Consumables
• Kits
• Reagents
• Antibodies
• Probes 
• Instruments
• Scanners
• Tissue Processing Systems
• Slide staining systems
• Others

By Technology (USD Million)

• Immunohistochemistry (IHC)
• In-situ hybridization (ISH)
• Special staining
• Digital pathology
• Management

By Application (USD Million)

• Breast Cancer
• Prostate Cancer
• Lung cancer
• Lymphoma
• Gastric Cancer
• Others

By End-use (USD Million)

• Hospitals
• Research laboratories
• Pharmaceutical companies
• CROs
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Poland
  • Switzerland
  • Norway
  • Finland
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Indonesia
  • Taiwan
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Israel